Prot#GS-US-295-0203: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS or BRAF Mutant Colorectal Adenocarcinoma that Has Progresse

Project: Research project

Project Details

Effective start/end date3/9/123/9/18


  • PRA Health Sciences (GS-US-295-0203)
  • Gilead Sciences, Inc. (GS-US-295-0203)